Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the Jefferies Virtual London Healthcare Conference on November 17, 2020. The presentation will be accessible via live webcast on Verrica's website.

The company is developing VP-102, a potential first-in-class treatment for molluscum contagiosum, with plans to resubmit its NDA in early 2021 following feedback from the FDA. VP-102 has completed Phase 2 studies for common and external genital warts, and Verrica is also working on VP-103 for treating plantar warts.

Positive

• Verrica plans to resubmit its NDA for VP-102 in Q1 2021, indicating progress in regulatory processes.
• Successful completion of Phase 2 studies for common and external genital warts showcases the potential effectiveness of VP-102.
• The expected brand name for VP-102, YCANTH™, suggests marketing readiness if approved.

Negative

• A Complete Response Letter from the FDA regarding VP-102 in July 2020 may create uncertainty for investors.
• Potential delays in the resubmission process could impact stock performance and investor confidence.

WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 2:55 p.m. ET. A live webcast of the event can be accessed in the Investors/Presentations & Events section of the Verrica website at http://www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class drug-device combination product containing a topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. In October 2020, Verrica participated in a Type A meeting with the FDA. Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@troutgroup.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@troutgroup.com

FAQ

When will Ted White present at the Jefferies Virtual London Healthcare Conference?

Ted White will present on November 17, 2020, at 2:55 p.m. ET.

What is VP-102 and its significance for Verrica?

VP-102 is a potential first-in-class drug-device combination for treating molluscum contagiosum, currently undergoing resubmission of its NDA.

What were the FDA's concerns regarding VP-102?

The FDA issued a Complete Response Letter in July 2020, which outlined concerns that need to be addressed before approval.

What other products is Verrica Pharmaceuticals developing?

In addition to VP-102, Verrica is also developing VP-103 for plantar warts.